Medtronic plc (MDT)
NYSE · Dublin, Ireland · Founded 1949 · CEO Geoffrey Martha
Valuation summary
$108.30 fair value versus $100.61 in the market, a difference of +7.6%. Rated Hold.
| Fair value per share | $108.30 |
| Current share price | $100.61 |
| Upside / downside | +7.6% |
| Bear case | $63.95 |
| Bull case | $172.95 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.50% |
| Market capitalisation | $129B |
| EV / Sales | 4.2x |
About Medtronic plc
Founded in 1949 by Earl Bakken in a Minneapolis garage, repairing medical equipment before building the first wearable external pacemaker. Geoffrey Martha has been CEO since 2020. Medtronic is the largest pure-play medical device company in the world, spanning cardiac rhythm management, cardiac ablation, surgical robotics and neuromodulation. Its diabetes business was listed separately as MiniMed in March 2026, and in September 2026 Medtronic launched an exchange offer to complete the separation. Its Irish domicile dates from the 2015 Covidien acquisition.
Investment case
- Enormous installed base and long-standing surgeon relationships create real switching friction.
- Pulsed field ablation is a genuinely new cardiac technology where Medtronic entered early, and cardiac ablation revenue rose 88% in the first quarter of fiscal 2027.
- Procedure volumes have recovered well and the demographic tailwind is durable.
Key risks
- Growth has trailed peers such as Boston Scientific and Stryker for several years.
- The Hugo surgical robot is far behind Intuitive's da Vinci in adoption.
- Diabetes has lost share to Dexcom and Abbott in continuous glucose monitoring.
Recent developments
- 2026-09-14 · Medtronic launched a split-off exchange offer for up to 225.4m MiniMed shares at a 7% discount, expiring 9 October 2026. source
- 2026-09-01 · Q1 FY27 revenue $9.76bn, up 13.7% organically including about $570m from an extra week; cardiac ablation up 88%; FY27 guidance raised. source
- 2026-09-01 · Medtronic is investing about $700m for rights to distribute Cornerstone Robotics' Sentire surgical robot alongside Hugo in select non-US markets. source
Revenue by segment
| Cardiovascular | 37% |
| Neuroscience | 29% |
| Medical Surgical | 25% |
| Diabetes | 9% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $41.0B | $6.7B |
| Year 2 | $45.0B | $7.4B |
| Year 3 | $49.3B | $8.1B |
| Year 4 | $54.0B | $8.8B |
| Year 5 | $59.0B | $9.7B |
What the street says
Generally seen as a solid but slower-growing franchise, though momentum has improved: the first quarter of fiscal 2027 beat expectations and organic growth guidance was raised to 7.25–7.75%. Pulsed field ablation and completion of the MiniMed separation are the main points of debate.
Comparable companies: SNY · SYK · ABT · TMO · BSX · AZN · IDXX · TAK
Open the interactive model, price chart and sensitivity grid →